Literature DB >> 7549063

Mechanisms of physiological fibrinolysis.

H R Lijnen1, D Collen.   

Abstract

The fibrinolytic system comprises an inactive proenzyme, plasminogen, that is converted by plasminogen activators to the active enzyme, plasmin, which degrades fibrin. Two immunologically distinct plasminogen activators (PA) have been identified: tissue-type plasminogen activator (t-PA) and urokinase-type plasminogen activator (u-PA). t-PA mediated plasminogen activation is mainly involved in the dissolution of fibrin in the circulation, whereas u-PA mediated plasminogen activation mainly plays a role in pericellular proteolysis. Plasminogen activation is regulated by specific molecular interactions between its main components, such as binding of plasminogen and t-PA to fibrin, or to specific cellular receptors resulting in enhanced plasminogen activation, inhibition of t-PA and u-PA by plasminogen activator inhibitors (PAI) and inhibition of plasmin by alpha 2-antiplasmin. Controlled synthesis and release of PAs and PAIs primarily from endothelial cells also contributes to the regulation of physiological fibrinolysis. The lysine binding sites situated in the kringle structures of plasminogen play a crucial role in the regulation of fibrinolysis by modulating its binding to fibrin and to cell surfaces, and by controlling the inhibition rate of plasmin by alpha 2-antiplasmin.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7549063     DOI: 10.1016/s0950-3536(05)80268-9

Source DB:  PubMed          Journal:  Baillieres Clin Haematol        ISSN: 0950-3536


  30 in total

1.  A catalytic switch and the conversion of streptokinase to a fibrin-targeted plasminogen activator.

Authors:  G L Reed; A K Houng; L Liu; B Parhami-Seren; L H Matsueda; S Wang; L Hedstrom
Journal:  Proc Natl Acad Sci U S A       Date:  1999-08-03       Impact factor: 11.205

2.  The antiangiogenic agent Neovastat (AE-941) stimulates tissue plasminogen activator activity.

Authors:  Denis Gingras; Dominique Labelle; Carine Nyalendo; Dominique Boivin; Michel Demeule; Chantal Barthomeuf; Richard Béliveau
Journal:  Invest New Drugs       Date:  2004-01       Impact factor: 3.850

3.  Reduction of steroid-induced intraocular pressure elevation in sheep by tissue plasminogen activator.

Authors:  Rosana Gerometta; Sandeep Kumar; Shaily Shah; Larry Alvarez; Oscar Candia; John Danias
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-12-03       Impact factor: 4.799

4.  Does Tranexamic Acid Improve Clot Strength in Severely Injured Patients Who Have Elevated Fibrin Degradation Products and Low Fibrinolytic Activity, Measured by Thrombelastography?

Authors:  Hunter B Moore; Ernest E Moore; Michael P Chapman; Kirk C Hansen; Mitchell J Cohen; Frederic M Pieracci; James Chandler; Angela Sauaia
Journal:  J Am Coll Surg       Date:  2019-03-29       Impact factor: 6.113

5.  Temperature-induced changes in the lipopolysaccharide of Yersinia pestis affect plasminogen activation by the pla surface protease.

Authors:  Marjo Suomalainen; Leandro Araujo Lobo; Klaus Brandenburg; Buko Lindner; Ritva Virkola; Yuriy A Knirel; Andrey P Anisimov; Otto Holst; Timo K Korhonen
Journal:  Infect Immun       Date:  2010-04-05       Impact factor: 3.441

6.  Peroxynitrite and fibrinolytic system: the effect of peroxynitrite on plasmin activity.

Authors:  Pawel Nowak; Joanna Kołodziejczyk; Barbara Wachowicz
Journal:  Mol Cell Biochem       Date:  2004-12       Impact factor: 3.396

7.  Matrix metalloproteinases production in malignant pleural effusions after talc pleurodesis.

Authors:  P D'Agostino; A Rao Camemi; R Caruso; F Arcoleo; A Cascio; A Dolce; E Sacco; G Cangemi; T di Rosa; P Moceo; E Cillari
Journal:  Clin Exp Immunol       Date:  2003-10       Impact factor: 4.330

8.  BBA70 of Borrelia burgdorferi is a novel plasminogen-binding protein.

Authors:  Arno Koenigs; Claudia Hammerschmidt; Brandon L Jutras; Denys Pogoryelov; Diana Barthel; Christine Skerka; Dominik Kugelstadt; Reinhard Wallich; Brian Stevenson; Peter F Zipfel; Peter Kraiczy
Journal:  J Biol Chem       Date:  2013-07-16       Impact factor: 5.157

9.  Simvastatin reduces circulating plasminogen activator inhibitor 1 activity in volunteers with the metabolic syndrome.

Authors:  Long Wang; Jason Rockwood; Danielle Zak; Sridevi Devaraj; Ishwarlal Jialal
Journal:  Metab Syndr Relat Disord       Date:  2008-06       Impact factor: 1.894

10.  C-reactive protein increases plasminogen activator inhibitor-1 expression in human endothelial cells.

Authors:  Changyi Chen; Bicheng Nan; Peter Lin; Qizhi Yao
Journal:  Thromb Res       Date:  2007-10-22       Impact factor: 3.944

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.